What Your Doctor Isn’t Telling You About Ozempic, Mounjaro, and the Future of Weight Loss
Curator’s Note: The article discusses the significant breakthrough of GLP-1 medications like Ozempic and Mounjaro, which help patients lose substantial weight—up to 22% of their total body weight. Despite their effectiveness, the article emphasizes that these drugs do not address the underlying metabolic issues that lead to weight gain, resulting in regaining weight after discontinuation. It highlights potential concerns such as muscle loss, gastrointestinal effects, gallbladder disease, thyroid risks, and psychological impacts related to food. Ultimately, the author advocates for a comprehensive approach that includes nutrition, exercise, and metabolic health to ensure lasting health improvements beyond medication. This premium content was provided by Dr. Shiv K. Goel, MD for the Digitalmehmet Content Ecosystem readers.
A functional medicine physician’s honest assessment of the most disruptive drugs in modern medicine — the science, the silence, and what happens after you stop the injection.
Something unprecedented is happening in medicine.
For the first time in decades, we have a class of medications that reliably produces significant weight loss in the majority of patients who take them. Not five pounds. Not ten. We are talking about 15 to 22 percent of total body weight — numbers that were previously achievable only through bariatric surgery.
Semaglutide. Tirzepatide. Ozempic. Wegovy. Mounjaro. Zepbound.
These names have crossed from medical journals into dinner table conversations, celebrity interviews, and social media debates with a speed that few pharmaceutical breakthroughs have ever matched.
And yet, for all the noise, there is a surprising amount of silence around the questions that matter most.
As a board-certified internist and functional medicine physician who has prescribed these medications, studied their mechanisms, and watched their effects unfold in real patients — I want to have the conversation your doctor may not have time for, and the one the pharmaceutical companies have no incentive to start.
What GLP-1 Medications Actually Do
To understand what these drugs are doing — and what they are not doing — we need to start with the biology.
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces in the small intestine after you eat. Its job is elegantly simple. It signals the brain that food has arrived. It slows gastric emptying so you feel full longer. It also stimulates insulin release to manage blood sugar.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) mimic this hormone at significantly higher concentrations than your body produces naturally. They amplify the satiety signal, profoundly reduce appetite, and slow the movement of food through your digestive system.
Tirzepatide (Mounjaro, Zepbound) takes this a step further. It is a dual agonist — activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism appears to produce even greater weight loss and metabolic improvement than GLP-1 alone.
The clinical results are striking. The STEP trials for semaglutide demonstrated average weight loss of approximately 15 percent of body weight. The SURMOUNT trials for tirzepatide showed losses reaching 22 percent. For a 250-pound patient, that translates to 37 to 55 pounds.
These are not marginal numbers. They are life-changing.
So what is the problem?
The Conversation No One Is Having
Here is what I tell my patients that many prescribers do not.
These medications do not fix the underlying problem.
They manage a symptom — excess appetite and disordered satiety signaling — with extraordinary effectiveness. But the metabolic dysfunction that caused the weight gain in the first place? The insulin resistance, the chronic inflammation, the hormonal imbalances, the gut dysbiosis, the sleep disruption, the stress-driven cortisol elevation? Those remain unaddressed.
This matters enormously because of one inconvenient fact that the excitement around these drugs has largely obscured:
When you stop taking them, the weight comes back.
The STEP 1 extension trial indicated that participants regained about two-thirds of their lost weight. This occurred within one year after discontinuing semaglutide. Two-thirds.
This is not a failure of the drug. It is performing exactly as designed — suppressing appetite for as long as it is present in the body. The moment that suppression is removed, the body’s underlying metabolic programming reasserts itself.
What Your Doctor Likely Isn’t Discussing
In my practice, I see patients who have been prescribed GLP-1 medications by other providers with minimal discussion of several critical issues:
1. Muscle Loss
Weight loss from GLP-1 agonists is not purely fat loss. Studies indicate that 25 to 40 percent of the weight lost can be lean muscle mass. For older adults, this is particularly concerning — loss of muscle mass accelerates sarcopenia, increases fall risk, weakens metabolic rate, and can leave patients thinner but more fragile.
This is why I insist that every patient on these medications follows a structured resistance training program. They must also maintain adequate protein intake. This should be a minimum of one gram per pound of lean body mass daily.
2. Gastrointestinal Impact
Nausea, vomiting, diarrhea, and constipation are among the most common side effects. But less discussed is the effect of dramatically slowed gastric emptying on the gut microbiome. When food sits in the stomach and intestines significantly longer than normal, it alters the bacterial environment.
3. Gallbladder Disease
Rapid weight loss from any cause increases gallstone risk. GLP-1 agonists are no exception. The FDA label includes warnings about gallbladder-related events, yet many patients report never having been counseled about this risk.
4. Thyroid Concerns
Animal studies have shown an association between semaglutide and thyroid C-cell tumors. GLP-1 medications carry a boxed warning — the FDA’s most serious category — regarding medullary thyroid carcinoma risk.
5. Psychological Relationship With Food
Perhaps the most underexplored dimension is psychological. Many patients describe a sudden and complete absence of food-related thoughts. But it also raises questions about what happens to the psychological patterns and emotional coping mechanisms that drove overeating.
The Functional Medicine Perspective
I am not anti-GLP-1. Let me be clear about that.
These medications are remarkable pharmacological tools. For patients with a BMI over 30, they can provide the metabolic breathing room needed. For those over 27 with metabolic comorbidities, these medications help break cycles of inflammation, insulin resistance, and weight-driven disease progression.
What I am against is the idea that a weekly injection is a complete solution.
In my practice at Prime Vitality, when I prescribe GLP-1 agonists, they are one component of a comprehensive protocol that includes:
- Hormonal improvement — Testing and addressing thyroid function, testosterone, estrogen, progesterone, DHEA, and cortisol
- Gut health restoration — Comprehensive stool analysis, identification of dysbiosis, and targeted interventions
- Targeted nutrition — Personalized macro and micronutrient protocols that preserve lean mass
- Resistance training — Non-negotiable for muscle preservation
- Metabolic monitoring — Tracking fasting insulin, HOMA-IR, hs-CRP, HbA1c, and lipid particle size
- Stress and sleep optimization — Because cortisol dysregulation independently drives insulin resistance
- Mindfulness practices — Meditation and breathwork to address emotional eating patterns
The goal is not just weight loss. The goal is metabolic transformation. This involves creating a physiological environment. When the medication is eventually reduced or discontinued, the body does not default back to its previous state.
What I Tell My Patients
If you are considering a GLP-1 medication, or if you are already on one, here is what I want you to know:
Use the window wisely. The appetite suppression these drugs provide is a window of opportunity — not a permanent solution. Use that window to rebuild your metabolic foundation.
Do not accept a prescription without a plan. If your provider hands you a prescription, but there is no discussion of nutrition, exercise, muscle preservation, or metabolic testing, you should ask questions. Demand more.
Monitor beyond the scale. Body composition, inflammatory markers, hormonal panels, and how you feel — these matter more than the number.
Protect your muscle. Resistance train. Eat protein. The weight you lose means nothing if you emerge weaker and more metabolically fragile.
Think long-term. The question is not whether these medications work. They work. The question is what your health looks like in five years.
The Real Revolution
The GLP-1 revolution is real. These drugs are changing lives. But the deeper revolution — the one I am far more interested in — is the shift toward understanding why metabolic dysfunction occurs in the first place and addressing it at its roots.
That revolution occurs by integrating conventional pharmacology with functional medicine. It also involves hormonal optimization, gut health, movement, sleep, stress management, and mindfulness.
It happens when we stop treating weight as a disease and start recognizing it as a symptom.
It happens when medicine meets mindfulness — and when we give patients not just a prescription, but a path.
Dr. Shiv K. Goel, MD, FACP, is a board-certified internist and functional medicine physician based in San Antonio, Texas. He is the founder of Prime Vitality, a holistic wellness center and medical spa. He is also the author of Healing the Split: Reconnecting Mind, Body, and Spirit in Modern Medicine. Follow his insights on Substack, Medium, and learn more at Prime Vitality Care.
You can learn more about Dr. Goel’s background from this detailed interview conducted by Dr. Mehmet Yildiz on Medium.com.
Leave a Reply